Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Recruiting now Phase 4 NCT06396416
Run by Western University, Canada · for 18 and older · All sexes
What this study is about
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Who can join (things the study team will check)
✅ You may be able to join if…
- Adults aged 18 years or older
- BMI; 35 kg/m\^2
- 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis
🚫 You may not be able to join if…
- Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity)
- Type 1 diabetes
- No access to semaglutide via drug coverage
- Pregnant, breastfeeding or planning to become pregnant
- Currently in a GLP-1RA or GLP-1RA/GIP study or planning to be in one
Where this trial is running
- London Health Sciences Centre, London, Ontario, Canada
Who to contact
Heather LaPier, BSc · 519-646-6100 · heather.lapier@sjhc.london.on.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06396416.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.